Processa Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 1.89 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.33M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metasta...